

Appendix CGuideline Comparison

Comparison of KDOQI, ADA, and JNC-VII Guidelines. Focus on CKD-Related Guidelines

KDOQI (NGC, from Am J Kidney Dis 2002 Feb)	ADA (in "Standards of Medical Care," Diabetes Care 30 (supp1) 2007 Jan)	JNC-VII
#1: Definition and Stages of CKD defined by GFR		
#2: Evaluation and Treatment. 1. CKD patients should be evaluated for diagnosis, comorbidities, severity, complications, risk for loss of kidney function, risk for	V.A. The comprehensive diabetes examination includes, among other components, tests for microalbuminuria and serum creatinine (and calculation of	Physical exam should include examination of the abdomen for enlarged kidneys, masses, and abnormal aortic pulsation
2. Treatment of CKD should include dx-based therapy, E&M of comorbidities, slowing loss of kidney function, prevention and treatment for CVD, cx of dec. kidney function, preparation for replacement, and replacement/transplant 3. Develop clinical action plan. 4. Review medication 5. Incorp. S/M into tx plan 6. Referral to nephrologist for	eGFR)	Routine laboratory tests recommended before initiating therapy includeblood glucose and hematocrit; serum potassium, creatinine (or the corresponding estimated glomerular filtration rate [GFR]), and calcium; and a lipid profile Optional tests include measurement of urinary albumin excretion or albumin/creatinine ratio
eGFR<30 #3: Patients at increased risk for CKD should be assessed		